patent.fyi
Applications  /  US 2026/0355196
United States Patent Application Publication

US 2026/0355196 A1

Published
Nov 12, 2026
Filed
May 9, 2024
Earliest date on the face
May 10, 2023
Classification
A61K 31/506
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Nitrile at the R position

What ifWhat if R were a nitrile group bonded through its carbon atom?
Claim language“R is halo”

The nitrile projects a narrow, linear group from the scaffold and withdraws electron density from the attachment site. Its terminal nitrogen serves as a hydrogen-bond acceptor.

1.10Hydroxyethoxy group at Q

What ifWhat if Q were an acyclic hydroxyethoxy group?
Claim language“Q is RQ, or Ring 5”

The group attaches through an ether oxygen and places a terminal hydroxyl two methylene units away. The ether oxygen accepts hydrogen bonds, and the terminal hydroxyl can donate and accept them.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Isoform profiling in veterinary cell cultures

An inhibitor panel is applied to primary canine fibroblast cultures to measure how PIP4K activity affects cellular phosphoinositide levels. Parallel cultures receive non-targeting small interfering RNA or small interfering RNA directed against one canine PIP4K2 isoform per condition. Lipids from compound-treated and vehicle-treated cultures are quantified by liquid chromatography coupled to mass spectrometry, with chromatographic separation of phosphatidylinositol bisphosphate positional isomers. The change in phosphatidylinositol 4,5-bisphosphate is compared across knockdown conditions and normalized to total cellular protein.

Parameter or scale variation

Linker extension beyond ten carbons

A matched degrader series contains linear linkers with 10, 12, and 14 methylene groups between two fixed terminal amide junctions. The same PIP4K-binding and ubiquitin ligase-binding groups are attached to both ends of each spacer. Cells receive an eight-point, threefold concentration series, and PIP4K abundance is measured at 2, 8, and 24 hours. Intracellular compound concentrations are measured in parallel to compare degradation at matched exposure.

Combination with existing systems

Degradation measurements under microfluidic perfusion

A glass microfluidic chamber holds an adherent cell layer and receives compound-containing medium or vehicle from two reservoirs connected through a switching valve. Cells express a PIP4K isoform with a luminescent peptide tag inserted at its endogenous locus. The valve delivers a compound pulse followed by compound-free medium, and a luminometer records the tagged protein signal during exposure and washout. A parallel vehicle channel supplies the baseline for signal drift, and outlet samples establish when the compound clears the chamber.

Automated or data-driven variant

Automated selection of degrader linker series

An automated liquid handler dispenses degrader candidates into assay plates containing cells with an endogenous PIP4K abundance reporter. Software fits concentration-response curves and records maximum protein loss, the concentration that produces half-maximal loss, and cell viability. A Gaussian process model uses linker length, rotatable bond count, and hydrogen-bond acceptor count to rank candidates from a predefined synthesis list. The next assay batch includes candidates with high predicted protein loss and candidates with high prediction uncertainty.

Specific version of a part

Carbon linked oxetane ring

Ring 3 is oxetan-3-yl and attaches to the scaffold through the carbon opposite the ring oxygen. The four-membered ring holds the ether oxygen two bonds from the attachment carbon along either ring path.

Para cyano phenyl ring

Ring 3 is a phenyl ring bearing a nitrile para to the scaffold attachment. The aromatic ring fixes the nitrile along the axis through the attachment carbon and the opposite ring carbon.

Carbon linked morpholine terminus

Ring 5 is morpholin-2-yl and attaches through a carbon adjacent to the ring oxygen. The six-membered ring contains an ether oxygen and a secondary amine at opposite positions.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2023/0013585 A1
Published
Jan 19, 2023
Filed
May 27, 2021
Class
A61K 31/4545
Document BUS 2023/0065527 A1
Published
Mar 2, 2023
Filed
Aug 12, 2021
Class
C07D 487/10
Claim 1
Document A
Document B
1.1R is halo
R4, R5, R6, R10, and R17 are each independently H, halogen, C1-3 alkyl, or C1-3 alkoxy;
A · US 2023/0013585 A1 · ¶
1.2Ring 4 is optional, and when present is a monocyclic ring selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R4a, 4- to 6-membered heterocyclyl optionally substituted with one or more R4a, phenyl optionally substituted with one or more R4b, and 5- to 6-membered heteroaryl optionally substituted with one or more R4b
R21 is i) H, ii) C3-7 monocyclic or bridged bicyclic cycloalkyl optionally substituted with 1-3 groups independently selected from —CN, —OH, halogen, C1-3 alkyl, and C1-3 alkoxy, wherein the C1-3 alkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, and C1-3 alkoxy, iii) 4-6 membered monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from N, O, and S, wherein the 4-6 membered monocyclic heterocyclyl is optionally subst
A · US 2023/0013585 A1 · ¶
R1, R6a1 and R6a2 can be independently selected from —C1-4 alkyl, —C1-4 haloalkyl, -monocyclic C3-6cycloalkyl, —(C1-4 alkyl)monocyclic C3-6cycloalkyl, 4-6 membered monocyclic heterocyclic ring, aryl(C1-4alkyl) and —(C1-4alkyl)5- or 6-membered monocyclic heteroaryl; wherein the —C3-6cycloalkyl, the 4-6 membered monocyclic heterocyclyl, the aryl(C1-4alkyl) and the -5- or 6-membered monocyclic heteroaryl(C1-4alkyl) is optionally substituted with one or two or three substituents
B · US 2023/0065527 A1 · ¶ 88
1.3Ring 3 is a monocyclic ring selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R3a
R7 is i) H, ii) C1-6 alkyl optionally substituted with 1-3 groups independently selected from —OH, halogen, C1-3 alkoxy, and C3-7 monocyclic cycloalkyl, or iii) C3-7 monocyclic cycloalkyl optionally substituted with 1-3 groups independently selected from —OH, halogen, C1-3 alkyl, and C1-3 alkoxy;
A · US 2023/0013585 A1 · ¶
R1, R6a1 and R6a2 can be independently selected from —C1-4 alkyl, —C1-4 haloalkyl, -monocyclic C3-6cycloalkyl, —(C1-4 alkyl)monocyclic C3-6cycloalkyl, 4-6 membered monocyclic heterocyclic ring, aryl(C1-4alkyl) and —(C1-4alkyl)5- or 6-membered monocyclic heteroaryl; wherein the —C3-6cycloalkyl, the 4-6 membered monocyclic heterocyclyl, the aryl(C1-4alkyl) and the -5- or 6-membered monocyclic heteroaryl(C1-4alkyl) is optionally substituted with one or two or three substituents
B · US 2023/0065527 A1 · ¶ 88
1.44- to 6-membered heterocyclyl optionally substituted with one or more R3a
R11 is i) 4-6 membered monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from N, O, and S, wherein the 4-6 membered monocyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —CN, —OH, halogen, oxo, C1-3 alkyl, and C1-3 alkoxy, ii) —S(O)2C1-6 alkyl, iii) —S(O)2C3-7 monocyclic cycloalkyl, iv) C1-6 alkyl optionally substituted with 1-3 groups independently selected from —CN, —OH, halogen, C1-3 alkoxy, and C3-7 monocyclic
A · US 2023/0013585 A1 · ¶
R1, R6a1 and R6a2 can be independently selected from —C1-4 alkyl, —C1-4 haloalkyl, -monocyclic C3-6cycloalkyl, —(C1-4 alkyl)monocyclic C3-6cycloalkyl, 4-6 membered monocyclic heterocyclic ring, aryl(C1-4alkyl) and —(C1-4alkyl)5- or 6-membered monocyclic heteroaryl; wherein the —C3-6cycloalkyl, the 4-6 membered monocyclic heterocyclyl, the aryl(C1-4alkyl) and the -5- or 6-membered monocyclic heteroaryl(C1-4alkyl) is optionally substituted with one or two or three substituents
B · US 2023/0065527 A1 · ¶ 88
1.5phenyl optionally substituted with one or more R3b
1.6or 5- to 6-membered heteroaryl optionally substituted with one or more R3b
A is a pyridinyl, pyridonyl, quinolinyl, or isoquinolinyl, each of which is optionally substituted with 1-4 R9; each R9 is independently i) halogen, ii) C1-6 alkoxy optionally substituted with 1-3 groups independently selected from —OH, halogen, C1-3 alkyl, and C3-7 monocyclic cycloalkyl, iii) —NH2, iv) —NH(C1-6 alkyl), wherein the C1-6 alkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, and C1-3 alkoxy, v) —N(C1-6 alkyl)2, wherein each C
A · US 2023/0013585 A1 · ¶
R1, R6a1 and R6a2 can be independently selected from —C1-4 alkyl, —C1-4 haloalkyl, -monocyclic C3-6cycloalkyl, —(C1-4 alkyl)monocyclic C3-6cycloalkyl, 4-6 membered monocyclic heterocyclic ring, aryl(C1-4alkyl) and —(C1-4alkyl)5- or 6-membered monocyclic heteroaryl; wherein the —C3-6cycloalkyl, the 4-6 membered monocyclic heterocyclyl, the aryl(C1-4alkyl) and the -5- or 6-membered monocyclic heteroaryl(C1-4alkyl) is optionally substituted with one or two or three substituents
B · US 2023/0065527 A1 · ¶ 88
1.7Ring 1 is a 4- to 8-membered cycloalkyl or saturated 4- to 8-membered heterocyclyl, each of which is optionally substituted with one or more R1
or a pharmaceutically acceptable salt thereof, wherein: one of R1 and R2 is H, —CN, —OH, halogen, or C1-6 alkyl, and the other of R1 and R2 is H, halogen, or C1-6 alkyl, wherein each C1-6 alkyl is optionally substituted with 1-3 groups independently selected from —OH and halogen, or R1 and R2 together with the carbon to which they are attached form a C3-7 monocyclic cycloalkyl or a 4-6 membered monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from N, O
A · US 2023/0013585 A1 · ¶
Ring A is selected from the group consisting of: a monocyclic C5-7 cycloalkyl substituted with R2a1; a bicyclic C6-12 cycloalkyl substituted with R2a2; a 5-7 membered nitrogen-containing monocyclic heterocyclyl, wherein a nitrogen of the 5-7 membered nitrogen-containing monocyclic heterocyclyl is optionally substituted with R2a3, wherein a carbon of the 5-7 membered nitrogen-containing monocyclic heterocyclyl is optionally substituted with R2a4 or R2a5, and wherein when R2a5
B · US 2023/0065527 A1 · claim 1
1.8V is a bond, —C1-4alkylene-, —C(O)—, —C(O)O-#, —OC(O)#-C1-4alkylene-C(O)-#, —C(O)N(RV)-#, —N(RV)C(O)-#, —OC(O)N(RV)-#, —N(RV)—C(O)O#, —C1-4alkylene-C(O)N(RV)-# or —C1-4alkylene-N(RV)C(O)-#
“Lower alkylene groups” are straight-chained —CH2— tethering groups, forming bonds to connect molecular fragments via their terminal carbon atoms. Examples include but are not limited to methylene (—CH2—), ethylene (—CH2CH2—), propylene (—CH2CH2CH2—) and butylene (—CH2CH2CH2CH2—).
B · US 2023/0065527 A1 · ¶ 30
1.9wherein # indicates the point of attachment to Ring 1
A wavy line drawn through a line in a structure indicates a point of attachment of a group.
A · US 2023/0013585 A1 · ¶ 102
1.10Q is RQ, or Ring 5
1.11wherein Ring 5 is selected from the group consisting of 3- to 10-membered cycloalkyl optionally substituted with one or more R5a, 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, and 5- to 12-membered heteroaryl optionally substituted with one or more R5b
R21 is i) H, ii) C3-7 monocyclic or bridged bicyclic cycloalkyl optionally substituted with 1-3 groups independently selected from —CN, —OH, halogen, C1-3 alkyl, and C1-3 alkoxy, wherein the C1-3 alkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, and C1-3 alkoxy, iii) 4-6 membered monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from N, O, and S, wherein the 4-6 membered monocyclic heterocyclyl is optionally subst
A · US 2023/0013585 A1 · ¶
Rm1 and Rm2 can be independently selected from hydrogen, —C1-4 alkyl, C3-6 monocyclic cycloalkyl, C5-12 bicyclic cycloalkyl, 5- or 6-membered monocyclic heteroaryl, 4-7 membered monocyclic heterocyclyl, 8-11 membered fused-heteroaryl, 8-11 membered fused-heterocyclyl and —Rx2; wherein the monocyclic heteroaryl, the bicyclic heteroaryl the monocyclic heterocyclyl and the bicyclic heterocyclyl contain at least one heteroatom independently selected from O (oxygen), S (sulfur), C
B · US 2023/0065527 A1 · ¶ 90
1.12or Q is of Formula (i) wherein: Ring A is selected from the group consisting of each of which is optionally substituted with one or more C1-4alkyl or halo X is a bond, —O—, —NH—, or —NHC(O)— Ring B is selected from the group consisting of each of which is optionally substituted with one or more halo, C1-4alkyl, C1-4haloalkyl, or OH, and wherein RD is H or C1-4alkyl wherein # indicates attachment to X W is a bond, —O—, —NH—, or —NHC(O)— Ring C is optional, and when present is 4- to 12-membered heterocyclyl optionally substituted with one or more RC Linker is a bond, —O—, C1-10alkylene, C1-10alkylene-N(Ry), C(O)C1-10alkylene, C(O)C1-10alkylene-N(Ry), C(O)N(Ry)C1-10alkylene, C(O)N(Ry)C1-10alkylene-N(Ry), C1-6alkylene-C(O)C1-10alkylene, C1-6alkylene-C(O)C1-10alkylene-N(Ry), C1-6alkylene-C(O)N(Ry)—C1-10alkylene, C1-6alkylene-C(O)N(Ry)—C1-10alkylene-N(Ry), or is of the formula *-L1-L2-L3-** wherein * indicates the point of attachment to Ring C when Ring C is present, and * indicates the point of attachment to W when Ring C is absent ** indicates the point of attachment to U when Ring 2 is present, and ** indicates the point of attachment to V when Ring 2 is absent L1 is a bond or C1-6 alkylene L2 is a 3- to 10-membered cycloalkyl or 4- to 12-membered heterocyclyl optionally substituted with one or more RL L3 is C1-10 alkylene, C1-10 alkylene-N(Ry), C(O)—C1-10alkylene, C(O)—C1-10alkylene-N(Ry), C(O)N(Ry)—C1-10alkylene, or C(O)N(Ry)—C1-10alkylene-N(Ry) U is absent when Ring 2 is absent, and is a bond or C(O) when Ring 2 is present Ring 2 is optional, and when present is selected from the group consisting of 3- to 10-membered cycloalkyl optionally substituted with one or more R2a, 4- to 12-membered heterocyclyl optionally substituted with one or more R2a, 6- to 12-membered aryl optionally substituted with one or more R2b, and 5- to 12-membered heteroaryl optionally substituted with one or more R2b each R1 is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, SO2Rx, SO2N(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)n—C1-4alkyl each R2a, R3a, R4a, and R5a is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)Rw, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo each R2b, R3b, R4b, and R5b is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)Rw, C1-4hydroxyalkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)nRx each RC is independently halo, OH, C1-4alkyl, or C1-4haloalkyl each RL is independently halo, OH, C1-4alkyl, or C1-4haloalkyl each RQ is independently H, halo, OH, C1-4alkyl, or C1-4haloalkyl each RV is independently H, halo, OH, C1-4alkyl, or C1-4haloalkyl each Rw is independently 3- to 10-membered cycloalkyl, phenyl optionally substituted with halo, or 4- to 12-membered heterocyclyl optionally substituted with hydroxyl, C1-4hydroxyalkyl, or C1-4aminoalkyl each Rx is independently C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)n—C1-4alkyl each Ry and Rz is independently H, C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O—C1-4alkyl, C1-4alkylene-NH—C1-4alkyl, C1-4alkylene-N(C1-4alkyl)-C1-4alkyl, 3- to 10-membered cycloalkyl, or C1-4alkylene-S(O)n—C1-4alkyl each n is independently 0, 1, or 2 wherein: (a) Ring 1 comprises an intraannular amide, or (b) V comprises an amide or carbamate, or (c) V is taken together with an atom of Ring 1, Ring 2, or Ring 5 to which it is attached, to form an amide or carbamate wherein: when Ring 3 is 5-membered heteroaryl, Ring 4 is present and is not cycloalkyl or tetrahydropyranyl when Ring 1 is 8-membered heterocyclyl, Ring 3 is phenyl substituted with CN, Ring 4 is absent, Q is RQ, and V is —OC(O)#, then RQ is not tert-butyl.
L1 is a cyclobutylene optionally substituted with 1-6 groups independently selected from —OH, halogen, C1-3 alkyl, and C1-3 alkoxy;
A · US 2023/0013585 A1 · ¶

An empty cell means only that no passage was reproduced there.

Statements in these documents
Current therapies utilizing these antibodies are highlighted by both significant and durable response to many different cancers but also by low overall response rates (<25%).
A · US 2023/0013585 A1 · ¶ 3
Accordingly, a small molecule inhibitor of HPK1 could provide a novel way to enhance anti-tumor immunity and also provide a way to increase the response to checkpoint receptor blockade.
A · US 2023/0013585 A1 · ¶ 4
There is an ongoing need for PD-1/PD-L1 therapies and improvements thereof for the treatment of disease.
B · US 2023/0065527 A1 · ¶ 3
Also disclosed herein are pharmaceutical compositions of compounds described herein and uses of or methods of using the compounds for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.
B · US 2023/0065527 A1 · ¶ 2
Cite aspatent.fyi, US 2026/0355196 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355196/, SHA-256 15326369c069d81be8496fc0186c50bad6f331694761eaae3475eb1e17333788
First published
Permanent addresshttps://patent.fyi/US20260355196/
Content fingerprint (SHA-256)15326369c069d81be8496fc0186c50bad6f331694761eaae3475eb1e17333788
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi